Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Allergan Inc patents (2017 archive)


Recent patent applications related to Allergan Inc. Allergan Inc is listed as an Agent/Assignee. Note: Allergan Inc may have other listings under different names/spellings. We're not affiliated with Allergan Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Allergan Inc-related inventors


Joint fat pad formulations, and methods of use thereof

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. ... Allergan Inc

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.. ... Allergan Inc

Animal product free system and process for purifying a botulinum toxin

Chromatographic processes and systems for purifying a botulinum toxin from an apf fermentation medium.. . ... Allergan Inc

Production of rounded salt particles

The present disclosure generally relates to methods of preparing spherical salt particles for industrial, medical, and other uses. The methods can include combining the angular salt particles with a quantity of finishing media, for example, into a receptacle. ... Allergan Inc

Process and system for obtaining botulinum neurotoxin

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.. . ... Allergan Inc

Fusion proteins and methods for treating, preventing or ameliorating pain

A single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site at which site the fusion protein is cleavable by a protease; a translocation domain capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.. . ... Allergan Inc

Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of formyl peptide receptor 2.. . ... Allergan Inc

Immediate release abuse deterrent tablet

The invention relates to an abuse deterrent immediate release tablet.. . ... Allergan Inc

Opioid receptor modulator dosage formulations

Abuse deterrent solid dosage formulations containing 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.. . ... Allergan Inc

Aspiration and injection device

An aspiration and injection device is provided that can allow for ergonomic, safe, and precise aspiration of a target site and ejection of a medicament to the target site. The device can include a syringe barrel, a flange extender couplable to the barrel, and plunger that can be engaged by a hand and/or one or more finger of a user to perform aspiration and injection at a target site.. ... Allergan Inc

Device and method for making a variable surface breast implant

Devices and methods are provided for making a variable textured breast implant when used in conjunction with a breast implant mandrel having a molding surface and a stem depending therefrom.. . ... Allergan Inc

Immuno-based botulinum toxin serotype a activity assays

The present specification discloses snap-25 compositions, methods of making α-snap-25 antibodies that bind an epitope comprising a carboxyl-terminus at the p1 residue from the bont/a cleavage site scissile bond from a snap-25 cleavage product, α-snap-25 antibodies that bind an epitope comprising a carboxyl-terminus at the p1 residue from the bont/a cleavage site scissile bond from a snap-25 cleavage product, methods of detecting bont/a activity, and methods of detecting neutralizing α-bont/a antibodies.. . ... Allergan Inc

09/28/17 / #20170273886

Stable hydrogel compositions including additives

The present specification generally relates to an injectable dermal filler composition that includes crosslinked hyaluronic acid-based polymer and an antioxidant.. . ... Allergan Inc

09/21/17 / #20170266344

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.. ... Allergan Inc

09/21/17 / #20170266201

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

09/21/17 / #20170266138

Methods of treatment of acne vulgaris using topical dapsone compositions

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.. ... Allergan Inc

09/14/17 / #20170258878

Bladder injeciton paradigm for administration of botulinum toxins

Methods for treating a bladder dysfunction by injecting a clostridial derivative to a target site below the bladder midline are described.. . ... Allergan Inc

09/07/17 / #20170256010

Patent alert system

A computerized publication system comprising an automated alert generation platform for use in monitoring patents or other documents in the public domain, combined with a subscription management module.. . ... Allergan Inc

08/31/17 / #20170248602

Immuno-based retargeted endopeptidase activity assays

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.. . ... Allergan Inc

08/10/17 / #20170224873

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

. . Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.. ... Allergan Inc

08/10/17 / #20170224786

Botulinum toxin compositions

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.. . ... Allergan Inc

08/03/17 / #20170218334

Cells useful for immuno-based botulinum toxin serotype a activity assays

The present specification discloses clonal cell lines susceptible to bont/a intoxication, methods of producing such clonal cell lines, and methods of detecting botulinum toxin serotype a activity using such clonal cell lines.. . ... Allergan Inc

08/03/17 / #20170216488

Stable hydrogel compositions including additives

Dermal filler hydrogel compositions, methods of making them, and methods of using them to treat soft tissue conditions, such as wrinkles, are provided. The compositions contain a crosslinked hyaluronic acid-based polymer and one or more additional ingredients, and are stable to sterilization by heat and/or pressure treatment. ... Allergan Inc

08/03/17 / #20170216414

Dermal filler

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.. . ... Allergan Inc

08/03/17 / #20170216326

Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of formyl peptide receptor 2 (fpr2).. . ... Allergan Inc

08/03/17 / #20170216253

Ketorolac tromethamine compositions for treating or preventing ocular pain

Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.. ... Allergan Inc

07/27/17 / #20170209532

Two part formulation system for ophthalmic delivery

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. ... Allergan Inc

07/06/17 / #20170189412

Androgen composition for treating an opthalmic condition

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. ... Allergan Inc

06/29/17 / #20170183298

Carbamoyl hydrazine derivatives as formyl peptide modulators

The present invention relates to carbamoyl hydrazine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the fpr receptor.. . ... Allergan Inc

06/29/17 / #20170183293

Novel ep4 agonists as therapeutic compounds

Described herein are compounds that are ep4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of ep4 receptors.. . ... Allergan Inc

06/29/17 / #20170182064

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.. . ... Allergan Inc

06/29/17 / #20170182062

4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.. ... Allergan Inc

06/29/17 / #20170182028

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

06/22/17 / #20170174858

Porogen compositions, methods of making and uses

Provided are porogen compositions and methods of using such porogen compositions in the manufacture of porous materials, for example, porous silicone elastomers. The porogens generally include comprising a core material and shell material different from the core material. ... Allergan Inc

06/22/17 / #20170174664

Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

06/22/17 / #20170173318

Multi-site injection system

A multi-site injection system includes a plurality of medicament delivering needles/microprotrusions, a needle/microprotrusion support, a supply of medicament, and a mechanism for providing the medicament to the plurality of needles/microprotrusions in order to effect delivery into a stratum corneum of a user.. . ... Allergan Inc

06/22/17 / #20170173123

Botulinum toxin treatments of neurological and neuropsychiatric disorders

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.. ... Allergan Inc

06/22/17 / #20170172983

Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.. . ... Allergan Inc

06/22/17 / #20170172982

Methods of treating alpha adrenergic mediated conditions

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.. ... Allergan Inc

06/22/17 / #20170172959

D-serine for the treatment of visual system disorders

The present invention relates to therapeutic methods using pharmaceutical compositions comprising one or a combination of co-agonists at the n-methyl-d-aspartate receptor for the treatment of visual system disorders.. . ... Allergan Inc

06/22/17 / #20170172957

D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders

The present invention relates to pharmaceutical compositions comprising d-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.. . ... Allergan Inc

06/08/17 / #20170157207

Method of treating conditions of the eye with an anti-vegf darpin

Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses.. . ... Allergan Inc

06/08/17 / #20170157138

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

06/01/17 / #20170152224

Novel prostamides for the treatment of glaucoma and related diseases

Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.. ... Allergan Inc

06/01/17 / #20170151367

Dry dermal filler compositions and methods of reconstitution

Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life.. . ... Allergan Inc

06/01/17 / #20170151261

Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations

A combination of a prostaglandin ep4 agonist and an effective amount of: a prostaglandin ep2 agonist, a skin growth factor, a small peptide, a small inhibitory rna targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine a2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars.. . ... Allergan Inc

06/01/17 / #20170151217

Stabilized oxymetazoline formulations and their uses

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.. ... Allergan Inc

05/18/17 / #20170136145

Dermal filler compositions including antioxidants

. . Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.. . ... Allergan Inc

05/18/17 / #20170136106

Botulinum toxin administration for treatment of neurogenic detrusor overactivity associated urinary incontinence

Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (ndo) and for reducing need for or frequency of clean intermittent catherization (cic) by injecting a clostridial derivative to the bladder of a patient are disclosed.. . ... Allergan Inc

05/11/17 / #20170128552

Methods for treating headache

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type a and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.. ... Allergan Inc

05/04/17 / #20170119737

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. . ... Allergan Inc

05/04/17 / #20170119703

Methods of treatment of acne vulgaris using topical dapsone compositions

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.. ... Allergan Inc

04/27/17 / #20170112853

Hypotensive lipid and timolol compositions and methods of using same

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. ... Allergan Inc

04/20/17 / #20170107279

Heavy chain only antibodies to ang-2

Disclosed herein are monospecific hcab antibodies with antigen-binding specificity to ang-2 and bispecific antibodies with antigen-binding specificities to ang-2 and vegf or pdgf.. . ... Allergan Inc

04/20/17 / #20170107210

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (pk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.. . ... Allergan Inc

04/13/17 / #20170100334

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

04/06/17 / #20170096423

Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation

. . Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the fp, dp, ep1, ep4, ip, dp1, fp and tp prostaglandin (pg) receptors thereby providing a general anti-inflammatory response.. . ... Allergan Inc

04/06/17 / #20170096401

Imidazole derivatives as formyl peptide receptor modulators

The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor.. . ... Allergan Inc

04/06/17 / #20170095466

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

04/06/17 / #20170095438

Compositions and methods for transdermal oxybutynin therapy

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as n-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. ... Allergan Inc

03/30/17 / #20170087273

Bioerodible matrix for tissue involvement

Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.. ... Allergan Inc

03/30/17 / #20170087163

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof. ... Allergan Inc

03/30/17 / #20170087102

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

03/23/17 / #20170081304

Quaternary ammonium alkyl esters as stable prodrugs

Disclosed herein are compounds according to formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (iop) or causing hair growth, and methods of using the same.. . ... Allergan Inc

03/23/17 / #20170080154

Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form

Described herein are injection devices capable of automatically injecting substances into the soft tissue of a patient. The devices can inject low to high viscosity materials at predetermined, user selected injection rates, allowing the operator more control than a traditional syringe. ... Allergan Inc

03/23/17 / #20170079956

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Disclosed herein is a method of upregulating regulatory t cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.. . ... Allergan Inc

03/16/17 / #20170071953

Microsphere drug delivery system for sustained intraocular release

Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. ... Allergan Inc

03/16/17 / #20170071882

Dapsone to treat rosacea

The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. ... Allergan Inc

03/16/17 / #20170071853

Intracameral sustained release therapeutic agent implants

Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. ... Allergan Inc

03/16/17 / #20170071726

Reinforced prosthetic implant with flexible shell

A fluid-filled soft prosthetic implant having a shell with a reinforced shell wall. The soft prosthetic implant may be for breast reconstruction or augmentation, or to restore the normal appearance of soft tissue in the buttocks, chin, calf, etc. ... Allergan Inc

03/09/17 / #20170066738

Compounds as tyrosine kinase modulators

The present invention is directed to novel compounds of formula i. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.. ... Allergan Inc

03/09/17 / #20170065612

Hypotensive lipid-containing biodegradable intraocular implants and related implants

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

03/09/17 / #20170065610

Compositions & methods for lowering intraocular pressure

Disclosed herein are compositions for lowering intraocular pressure (iop) of an eye comprising a combination iop-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing iop in the eye of a subject.. ... Allergan Inc

03/02/17 / #20170056412

Prostamide-containing intraocular implants and methods of use thereof

. . Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. ... Allergan Inc

03/02/17 / #20170056399

Sustained drug delivery implant

Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.. . ... Allergan Inc

03/02/17 / #20170055561

Conditioned cell culture medium compositions and methods of use

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. ... Allergan Inc

02/23/17 / #20170049559

Lighter weight implant

A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.. ... Allergan Inc

02/16/17 / #20170044247

Heavy chain only antibodies to pdgf

Disclosed herein are monospecific hcab antibodies with antigen-binding specificity to pdgf and bispecific antibodies with antigen-binding specificities to pdgf-2 and vegf or to pdgf and ang-2.. . ... Allergan Inc

02/16/17 / #20170042984

Methods for treatment of incontinence associated with sexual activity

The invention provides compositions and methods for treating incontinence associated with sexual activity.. . ... Allergan Inc

02/02/17 / #20170029469

Cyclosporin analogs

Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.. . ... Allergan Inc

02/02/17 / #20170028102

Silk medical devices

Laminate medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble silk film.. ... Allergan Inc

02/02/17 / #20170027679

Medical device with anti adhesive property

Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.. ... Allergan Inc

01/26/17 / #20170021057

Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. ... Allergan Inc

01/26/17 / #20170020997

Method for treating premature ejaculation with a botulinum neurotoxin

Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.. . ... Allergan Inc

01/26/17 / #20170020954

Therapeutic methods using cyclosporine components

Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.. ... Allergan Inc

01/26/17 / #20170020657

Soft filled prosthesis shell with variable texture

A soft prosthetic implant, such as a silicone breast implant, is provided. The implant has a variety of different surfaces, for example, different textures, located on different areas of the outer surface of the implant.. ... Allergan Inc

01/12/17 / #20170007560

Methods for treatment of pelvic pain and/or comorbid conditions

Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of ic/bps, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. ... Allergan Inc

01/05/17 / #20170000949

Mechanisms for injection and dosing

A mechanically operable handpiece is provided which allows a physician to easily deliver repeated, incremental doses of a beneficial composition, for example, a dermal filler gel, superficially into skin.. . ... Allergan Inc

01/05/17 / #20170000944

Needle for delivery of dermal filler threads

Provided herewith is a needle for delivering dermal filler thread to a wrinkle in a patient. The needle can also be used to deliver the thread to a patient for the purposes of facial contouring. ... Allergan Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Allergan Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergan Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###